In an opinion piece for The Guardian, Professor Matthew Snape discusses the initial results of his team's antibody study in the context of coronavirus risk to school children.
Congratulations to Professor Andrew Pollard who is the Winner of the Policy Engagement category in the Vice-Chancellor Innovation Awards 2020 for his work on Global policy on typhoid vaccines through research at Oxford!
A team of scientists at Oxford Vaccine Group (Department of Paediatrics) and Oxford University\u2019s Jenner Institute has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus.
First results of the What\u2019s the STORY (Serum Testing Of Representative Youngsters) trial indicate higher resilience of children to COVID-19 compared to other respiratory illnesses.
The European Commission has granted Marketing Authorisation to Janssen for a new Ebola vaccine, developed in partnership with the University of Oxford.
The Duke of Cambridge visits the University of Oxford\u2019s Oxford Vaccine Centre, to learn more about their work to establish a viable vaccine against COVID-19.
AstraZeneca has reached an agreement with Europe\u2019s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford\u2019s COVID-19 vaccine, with deliveries starting by the end of 2020.
Bristol Science Film Festival awarded the Professional Science Fact Film Prize to \"The Adventures of Alice in Typhoidland\" co-created by the Oxford Vaccine Group.
The Government has announced \u00a365.5 million of new funding for the vaccine being developed at the Oxford Vaccine Group as coronavirus vaccine trials accelerate.
The University of Oxford has today announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the COVID-19 vaccine candidate currently being trialled by the Oxford Vaccine Group.
University of Oxford researchers have begun testing a COVID-19 vaccine in human volunteers in Oxford today. Around 1,110 people will take part in the trial, half receiving the vaccine and the other half (the control group) receiving a widely available meningitis vaccine.
A multi-site project, called \u2018What\u2019s the STORY?\u2019 has received funding from UK Research and Innovation (UKRI) to assess novel coronavirus infection rates in children and teenagers across the UK. Given the importance of this study to the national Covid-19 response it has been deemed a priority study for the National Institute for Health Research\u2019s (NIHR) Urgent Public Health Response.
Five projects from across Oxford University's Medical Sciences Division, including a project led by Professor Matthew Snape from the Oxford Vaccine Group, are among twenty-one new studies into the novel coronavirus which have been funded by the UK government.
University of Oxford researchers working in an unprecedented vaccine development effort to prevent COVID-19 have started screening healthy volunteers (aged 18-55) today for their upcoming ChAdOx1 nCoV-19 vaccine trial in the Thames Valley Region. The vaccine based on an adenovirus vaccine vector and the SARS-CoV-2 spike protein is already in production but won\u2019t be ready for some weeks still.
A new exhibition tells the story of Oxford\u2019s role in the fight against typhoid, from pioneering efforts to eliminate typhoid in the era of Lewis Carroll\u2019s Alice in Wonderland to game-changing present-day vaccine trials.
A large field study of typhoid conjugate vaccine (TCV) in Nepal has shown a single dose to be safe and effective in reducing typhoid in children aged 9 months to <16 years in an endemic setting.
![\"A](\"https://www.ovg.ox.ac.uk/news/there-is-now-clear-data-on-covid-19-and-children-it-should-be-safe-to-reopen-english-schools/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n